Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placental-derived undifferentiated mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Kasr Al Ainy Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrauterine
01
Overview
Placental-derived undifferentiated mesenchymal stem cells (MSCs) is an investigational cell-based biologic therapy being developed and evaluated at Kasr El Aini Hospital. This regenerative medicine approach is intended to treat infertility in women undergoing intracytoplasmic sperm injection (ICSI) who suffer from recurrent implantation failure (RIF) or endometrial dysfunction, such as an unresponsive or atrophic endometrium. The therapy involves the intrauterine administration of MSCs isolated from placental tissue. These undifferentiated cells are deposited into the uterine cavity post-menstrually via an intrauterine insemination (IUI) catheter, allowing a 7-10 day window for the cells to differentiate in situ and promote endometrial regeneration. The treatment aims to improve endometrial receptivity and vascularity, thereby increasing the success rates of embryo implantation.
- Other names
- undifferentiated mesenchymal stem cells-Kasr El Aini Hospital-recurrent implantation failure-infertilityundifferentiated placental MSCsundifferentiated mesenchymal stem cells
Beyond the preview
Go deeper on placental-derived undifferentiated mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placental-derived undifferentiated mesenchymal stem cells.